



OMT grants unlimited OmniRat, OmniMouse and OmniFlic license

Palo Alto, CA, October 1, 2014

Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT's three OmniAb™ platforms, OmniRat®, OmniMouse® and OmniFlic™.

Dr. Roland Buelow, founder and CEO of OMT, commented, "Genmab is a pioneer in the use of transgenic mice to develop therapeutic antibodies. OMT's next generation transgenic animals will help Genmab create human antibody specificities for its DuoBody®, HexaBody™ and other new technologies and thus aid in creating therapeutic antibodies with superior efficacy."

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for creation of human therapeutic antibodies, *naturally optimized human antibodies*®, and the only company in the world with three transgenic animal platforms, *OmniAb*™.

OmniRat® is the industry's first human monoclonal antibody technology based on rats. OMT, in collaboration with Pfizer, has shown that OmniRat has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as a wild-type animals make rat antibodies. *OmniMouse*® is a transgenic mouse that complements OmniRat and expands epitope coverage. Both deliver human antibodies with high affinity, specificity, expression, solubility and stability. *OmniFlic*™ is the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies.

OMT's antibody platforms have broad freedom to operate and use technology protected by new patents and patent applications. They are available for licensing worldwide for all targets and indications. OMT has granted unlimited platform access to Genmab, Genentech, Janssen, Merck KGaA, Pfizer, Roche, Symphogen and an undisclosed global pharmaceutical company as well as individual target rights to smaller biotech and international companies. The Genentech partnership includes forward engineering of OmniRat that is made available to all OMT's partners. OmniAb antibody discovery services are also available via US-based Antibody Solutions, Europe-based Aldevron and China-based WuXi AppTec.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications, a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates. Partnering of selected innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

For more information visit www.omtinc.net or contact Brian Lundstrom, Chief Business Officer, Open Monoclonal Technology, Inc., Phone: +1-775-420-7750, E-mail: bl@omtinc.net.